Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Leukemia, Myeloid, Acute 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Carcinoma, Non-Small-Cell Lung 13Multiple Myeloma 12Lymphoma, Large B-Cell, Diffuse 11Lymphoma 11Hodgkin Disease 11Lymphoma, Non-Hodgkin 10Lymphoma, Follicular 8Neoplasms 7Lymphoma, Mantle-Cell 7Leukemia, Lymphocytic, Chronic, B-Cell 7Burkitt Lymphoma 7Breast Neoplasms 7Unspecified Adult Solid Tumor, Protocol Specific 6Recurrence 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Neuroblastoma 6Blast Crisis 6Sezary Syndrome 5Prostatic Neoplasms 5Myeloproliferative Disorders 5Myelodysplastic Syndromes 5Mycosis Fungoides 5Lymphoma, T-Cell, Cutaneous 5Lymphoma, Large-Cell, Immunoblastic 5Lymphoma, Large-Cell, Anaplastic 5Lymphoma, Extranodal NK-T-Cell 5Lymphoma, B-Cell, Marginal Zone 5Brain Neoplasms 5

Interventions

Nivolumab 8Paclitaxel 6Sirolimus 5Bevacizumab 5temsirolimus 4Pemetrexed 4Ipilimumab 4Docetaxel 4Carboplatin 4ARRY-334543 4Gemcitabine 3Erlotinib Hydrochloride 3olaparib 2linrodostat 2apatinib 2anlotinib 2abemaciclib 2Vorinostat 2Sunitinib 2Magnetic Resonance Spectroscopy 2Irinotecan 2Everolimus 2Doxorubicin 2Dasatinib 2Chlorogenic Acid 2Cetuximab 26-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline 2vorolanib 1vistusertib 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Advanced Cancer × Vorinostat × Clear all
NCT01087554 2026-01-16

Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
249 enrolled

Advanced Cancer

NCT01339871 2017-06-16

Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Completed
152 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡